Oncology Venture sells two candidates – receives USD 30 million in milestone payments
Biotech company Oncology Venture divests two of its drug candidates to Norwegian CRO. The deal includes milestone payments that could surpass USD 30 million as well as potential sales royalties. CFO is pleased.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY IDA JACOBSEN
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.